Venture
Dewpoint Therapeutics, Inc.
Latest Form D 2026-07-13- CIK 1828893
- State MA
- Biotechnology
- 3 Form D offerings since 2020-11-02
- Total sold
- $304M
- across 3 offerings
- Rounds
- 3
- Form D offerings since 2020-11-02
- Latest round
- $77.2M
- 2025-09-23 · 021-558346
- Investors
- 23
- on the latest round
Connected
named in its Form D filingsOfferings · since 2020-11-023 Form D offeringsExemptions506(b)People · Item 3Ameet Nathwani, M.D. + 10 moreInvestors · dashboard2 inferred investors
Dewpoint Therapeutics, Inc.CIK 1828893
Round timeline
amount sold · by first filed2025-09-23 · $77.2M
- 2020-11-02$77.1M021-379484
- 2022-02-04$150M021-432397
- 2025-09-23$77.2M021-558346
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($150M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-558346 | First filed2025-09-23 | Latest2026-07-13 | Sought$82.3M | Sold$77.2M | Investors23 | Exemptions506(b) |
| 021-432397 | First filed2022-02-04 | Latest2022-02-04 | Sought$150M | Sold$150M | Investors18 | Exemptions506(b) |
| 021-379484 | First filed2020-11-02 | Latest2020-11-02 | Sought$77.1M | Sold$77.1M | Investors25 | Exemptions506(b) |
Who backs Dewpoint Therapeutics, Inc. — 2 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2026-07-13
| Name | Relationship |
|---|---|
| Ameet Nathwani, M.D. | RelationshipExecutive Officer, Director |
| Srinivas Akkaraju, M.D., Ph.D. | RelationshipDirector |
| Regina Barzilay, Ph.D. | RelationshipDirector |
| Olivier Brandicourt, M.D. | RelationshipDirector |
| Giuseppe A. Ciaramella, Ph.D. | RelationshipDirector |
| Anthony A. Hyman, Ph.D. | RelationshipDirector |
| Mark Murcko, Ph.D. | RelationshipDirector |
| Amir H. Nashat, Sc.D. | RelationshipDirector |
| Steven Neier, Ph.D. | RelationshipDirector |
| Richard A. Young, Ph.D. | RelationshipDirector |
| Isaac A. Klein, M.D., Ph.D. | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2020-11-02
- Latest filing
- 2026-07-13
Who backs Dewpoint Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗